MARKET

CDNA

CDNA

CareDx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

64.53
-1.82
-2.74%
After Hours: 64.53 0 0.00% 16:54 03/05 EST
OPEN
67.26
PREV CLOSE
66.35
HIGH
67.26
LOW
56.82
VOLUME
1.74M
TURNOVER
--
52 WEEK HIGH
99.83
52 WEEK LOW
13.04
MARKET CAP
3.34B
P/E (TTM)
-156.8546
1D
5D
1M
3M
1Y
5Y
HLA Typing Market Is Expected To Reach USD 990.12 Million By 2026 From USD 659.75 Million In 2020, At A CAGR Of ~7.0%
Japan, Japan, Wed, 03 Mar 2021 23:35:28 / Comserve Inc. / -- Some of the prominent players in the HLA Typing Market are Thermo Fisher Scientific, Inc.,...
Comserve · 1d ago
Telemedicine and Wellness Apps Have Showcased Tremendous Growth Due To Pandemic
, /PRNewswire/ -- Telemedicine is one of those markets that has actually thrived because of the pandemic. Telemedicine, technicity, is the exchange of medical information from one location to another using electronic communication, which improves patient ...
PR Newswire - PRF · 3d ago
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Feb. 26, 2021: TWST, TMO, RHHBY, GOOGL, CDNA, TSM, SNPS, SNAP, ICE, NVS, PINS, REGN, ROKU, FLIR, AMZN, AAPL, FB, CRM, BABA, TCEHY
Twist Bioscience (TWST) - 51,404 Thermo Fisher Scientific (TMO) - 46,642 Roche (RHHBY) - 54,800 Alphabet (GOOGL) - 10,400 CareDx (CDNA) - 101,014 Taiwan Semiconductor Manufacturing (TSM) - 938,701 Synopsys (SNPS)
Benzinga · 6d ago
Exclusive: New CareDX CEO Reg Seeto Talks Transplantation Care Provider's Mission, Vision, Growth Drivers
Benzinga recently spoke with CareDx Inc (NASDAQ: CDNA) CEO Reginald Seeto to discuss the diagnostics surveillance solution provider's business, financials, market opportunity, alliances and future focus areas.
Benzinga · 6d ago
Is CareDx, Inc (NASDAQ:CDNA) Worth US$79.3 Based On Its Intrinsic Value?
Does the February share price for CareDx, Inc ( NASDAQ:CDNA ) reflect what it's really worth? Today, we will estimate...
Simply Wall St. · 02/26 05:31
Cathie Wood's ARK Invest Posts Fund Sales For Thursday, Feb. 25, 2021: LSPD, SCHW, GWRE, TCEHY, AMZN, TWST, CDNA, PINS, TSM, SNAP, SE, ROKU, REGN, NVS, GOOG, XLNX, ADSK, SNPS, ROK, FLIR, CRM, AAPL, BABA
Lightspeed (LSPD) - 59,324 Shares Charles Schwab (SCHW) - 246,711 Guidewire Software (GWRE) - 19,579 Tencent (TCEHY) - 192,478 Amazon (AMZN) - 9,736 Twist Bioscience (TWST) - 41,202 CareDx (CDNA) -
Benzinga · 02/26 00:24
Impact of Covid-19 Global HLA Typing For Transplant Market with Top Keyplayers- THERMO FISHER SCIENTIFIC, F. HOFFMAN-LA ROCHE LIMITED, QIAGEN, IMMUCOR
Heraldkeepers · 02/25 16:46
DJ CareDx Price Target Cut to $98.00/Share From $101.00 by Raymond James
Dow Jones · 02/25 13:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDNA. Analyze the recent business situations of CareDx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDNA stock price target is 98.00 with a high estimate of 105.00 and a low estimate of 93.00.
EPS
Institutional Holdings
Institutions: 344
Institutional Holdings: 59.95M
% Owned: 115.68%
Shares Outstanding: 51.82M
TypeInstitutionsShares
Increased
79
6.34M
New
79
-521.88K
Decreased
78
4.90M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Executive Director
Peter Maag
President/Chief Executive Officer/Director
Reginald Seeto
Chief Financial Officer
Marcel Konrad
Chief Marketing Officer
Sasha King
Lead Director/Independent Director
Michael Goldberg
Independent Director
George Bickerstaff
Independent Director
Frederick Cohen
Independent Director
Grace Colon
Independent Director
Christine Cournoyer
Independent Director
William Hagstrom
Independent Director
Fred Cohen
Independent Director
Ralph Snyderman
No Data
  • All
  • Financials
  • Insiders
More
About CDNA
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Webull offers kinds of CareDx Inc stock information, including NASDAQ:CDNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDNA stock methods without spending real money on the virtual paper trading platform.